Athersys Shares Outstanding 2006-2019 | ATHX

Athersys shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Athersys Annual Shares Outstanding
(Millions of Shares)
2018 137
2017 112
2016 85
2015 83
2014 79
2013 58
2012 33
2011 23
2010 19
2009 19
2008 19
2007 11
2006 0
2005 0
Athersys Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 146
Q4 2018 137
Q3 2018 139
Q2 2018 139
Q1 2018 127
Q4 2017 112
Q3 2017 115
Q2 2017 112
Q1 2017 102
Q4 2016 85
Q3 2016 86
Q2 2016 85
Q1 2016 84
Q4 2015 83
Q3 2015 83
Q2 2015 84
Q1 2015 79
Q4 2014 79
Q3 2014 78
Q2 2014 79
Q1 2014 76
Q4 2013 58
Q3 2013 59
Q2 2013 58
Q1 2013 53
Q4 2012 33
Q3 2012 30
Q2 2012 29
Q1 2012 26
Q4 2011 23
Q3 2011 24
Q2 2011 24
Q1 2011 22
Q4 2010 19
Q3 2010 19
Q2 2010 19
Q1 2010 19
Q4 2009 19
Q3 2009 19
Q2 2009 19
Q1 2009 19
Q4 2008 19
Q3 2008 19
Q2 2008 19
Q1 2008 19
Q4 2007 11
Q3 2007 19
Q2 2007 5
Q1 2007 0
Q4 2006 0
Q3 2006 0
Q2 2006 0
Q1 2006 1
Q3 2005 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.234B $0.024B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.422B 12.15
Gilead Sciences (GILD) United States $86.782B 10.54
Celgene (CELG) United States $64.715B 10.96
Biogen (BIIB) United States $45.297B 8.60
Vertex Pharmaceuticals (VRTX) United States $45.172B 54.60
Illumina (ILMN) United States $44.437B 51.50
CSL (CSLLY) Australia $35.310B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.586B 15.32
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.590B 15.61
Incyte (INCY) United States $17.453B 70.77
BioMarin Pharmaceutical (BMRN) United States $15.040B 0.00
Exact Sciences (EXAS) United States $15.005B 0.00
SINO PHARMACEUT (SBMFF) China $14.407B 0.00
Sarepta Therapeutics (SRPT) United States $11.635B 0.00
Genmab (GNMSF) Denmark $11.067B 56.26
Array BioPharma (ARRY) United States $10.358B 0.00
Seattle Genetics (SGEN) United States $10.323B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $9.032B 29.67
Galapagos (GLPG) Belgium $8.749B 0.00
Guardant Health (GH) United States $8.099B 0.00
Bio-Techne Corp (TECH) United States $7.974B 54.41
Alnylam Pharmaceuticals (ALNY) United States $7.755B 0.00
Bluebird Bio (BLUE) United States $7.483B 0.00
Amarin (AMRN) Ireland $7.232B 0.00
Exelixis (EXEL) United States $6.464B 16.48
BeiGene (BGNE) Cayman Islands $5.733B 0.00
Ascendis Pharma (ASND) Denmark $4.717B 0.00
Moderna (MRNA) United States $4.711B 0.00
Blueprint Medicines (BPMC) United States $4.686B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.616B 0.00
Horizon Pharma Public (HZNP) Ireland $4.348B 11.20
Repligen (RGEN) United States $4.059B 101.12
ACADIA Pharmaceuticals (ACAD) United States $3.852B 0.00
Mirati Therapeutics (MRTX) United States $3.805B 0.00
Spark Therapeutics (ONCE) United States $3.765B 0.00
China Biologic Products (CBPO) China $3.689B 23.43
Alkermes (ALKS) Ireland $3.662B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.369B 0.00
MorphoSys AG (MOR) Germany $3.287B 0.00
Arena Pharmaceuticals (ARNA) United States $3.077B 6.25
Amicus Therapeutics (FOLD) United States $2.888B 0.00
Immunomedics (IMMU) United States $2.724B 0.00
Medicines (MDCO) United States $2.713B 0.00
UniQure (QURE) Netherlands $2.633B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.607B 0.00
Reata Pharmaceuticals (RETA) United States $2.582B 0.00
Halozyme Therapeutics (HALO) United States $2.461B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.328B 0.00
MyoKardia (MYOK) United States $2.314B 0.00
Ligand Pharmaceuticals (LGND) United States $2.291B 18.98
Emergent Biosolutions (EBS) United States $2.238B 19.44
Akcea Therapeutics (AKCA) United States $2.178B 0.00
Acceleron Pharma (XLRN) United States $2.159B 0.00
NeoGenomics (NEO) United States $2.133B 139.63
Genomic Health (GHDX) United States $2.121B 45.04
Zai Lab (ZLAB) China $2.116B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.064B 0.00
Denali Therapeutics (DNLI) United States $1.970B 0.00
Myriad Genetics (MYGN) United States $1.912B 19.02
REGENXBIO (RGNX) United States $1.759B 0.00
Insmed (INSM) United States $1.725B 0.00
Cambrex (CBM) United States $1.523B 19.25
AnaptysBio (ANAB) United States $1.504B 0.00
Fate Therapeutics (FATE) United States $1.443B 0.00
Innoviva (INVA) United States $1.428B 3.95
RA PHARMCTL INC (RARX) United States $1.404B 0.00
Sangamo Therapeutics (SGMO) United States $1.384B 0.00
Athenex (ATNX) United States $1.341B 0.00
Alector (ALEC) United States $1.309B 0.00
Coherus BioSciences (CHRS) United States $1.308B 0.00
Editas Medicine (EDIT) United States $1.245B 0.00
Epizyme (EPZM) United States $1.240B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.188B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.050B 0.00
Codexis (CDXS) United States $1.022B 0.00
Cara Therapeutics (CARA) United States $1.010B 0.00
Adverum Biotechnologies (ADVM) United States $0.986B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.26
Dicerna Pharmaceuticals (DRNA) United States $0.970B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.950B 0.00
Principia Biopharma (PRNB) United States $0.945B 0.00
Twist Bioscience (TWST) United States $0.942B 0.00
Zymeworks (ZYME) Canada $0.936B 0.00
WAVE Life Sciences (WVE) Singapore $0.925B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.924B 0.00
Retrophin (RTRX) United States $0.879B 0.00
Vericel (VCEL) United States $0.861B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Arvinas (ARVN) United States $0.805B 0.00
Intellia Therapeutics (NTLA) United States $0.767B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.719B 33.92
Precision BioSciences (DTIL) United States $0.693B 0.00
Clovis Oncology (CLVS) United States $0.687B 0.00
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Zealand Pharma (ZEAL) Denmark $0.676B 7.90
Cellectis S.A (CLLS) France $0.654B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.646B 0.00
Cytokineticsorporated (CYTK) United States $0.639B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.631B 0.00
Intra-Cellular Therapies (ITCI) United States $0.630B 0.00
Heska (HSKA) United States $0.629B 64.40
DBV Technologies S.A (DBVT) France $0.621B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.575B 0.00
Anika Therapeutics (ANIK) United States $0.573B 19.58
MiMedx (MDXG) United States $0.561B 0.00
Revance Therapeutics (RVNC) United States $0.552B 0.00
Stemline Therapeutics (STML) United States $0.551B 0.00
CytomX Therapeutics (CTMX) United States $0.534B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.503B 0.00
PHARMA MAR SA (PHMMF) Spain $0.459B 0.00
UROGEN PHARMA (URGN) United States $0.446B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.433B 0.00
Gritstone Oncology (GRTS) United States $0.395B 0.00
Prothena (PRTA) Ireland $0.386B 0.00
Biofrontera AG (BFRA) Germany $0.385B 0.00
Scholar Rock Holding (SRRK) United States $0.376B 0.00
PDL BioPharma (PDLI) United States $0.373B 8.91
AC Immune SA (ACIU) Switzerland $0.372B 23.96
Arcus Biosciences (RCUS) United States $0.371B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.366B 0.00
Bellus Health (BLUSF) Canada $0.359B 0.00
Merus (MRUS) Netherlands $0.358B 0.00
Avid Bioservices (CDMO) United States $0.352B 0.00
BioDelivery Sciences (BDSI) United States $0.350B 0.00
Albireo Pharma (ALBO) United States $0.347B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.343B 0.00
Prometic Life Sciences (PFSCD) Canada $0.341B 0.00
Agenus (AGEN) United States $0.341B 0.00
Senesco Technologies (ELOX) United States $0.338B 0.00
Starpharma Holdings (SPHRY) Australia $0.337B 0.00
Theratechnologies (THERF) Canada $0.330B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Syros Pharmaceuticals (SYRS) United States $0.319B 0.00
Acorda Therapeutics (ACOR) United States $0.316B 5.56
AMAG Pharmaceuticals (AMAG) United States $0.312B 0.00
Sorrento Therapeutics (SRNE) United States $0.308B 0.00
Protagonist Therapeutics (PTGX) United States $0.308B 0.00
Kindred Biosciences (KIN) United States $0.305B 0.00
Inovio Pharmaceuticals (INO) United States $0.290B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.271B 0.00
Cellular Biomedicine (CBMG) United States $0.266B 0.00
PHASEBIO PHARMA (PHAS) United States $0.263B 0.00
Dynavax Technologies (DVAX) United States $0.263B 0.00
Sutro Biopharma (STRO) United States $0.262B 0.00
ChromaDex (CDXC) United States $0.250B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.243B 0.00
Kamada (KMDA) Israel $0.236B 9.16
ADMA Biologics Inc (ADMA) United States $0.233B 0.00
Cel-Sci (CVM) United States $0.231B 0.00
Geron (GERN) United States $0.229B 0.00
Palatin Technologies (PTN) United States $0.226B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.210B 0.00
Synlogic (SYBX) United States $0.210B 0.00
Cerecor (CERC) United States $0.208B 0.00
Abeona Therapeutics (ABEO) United States $0.207B 0.00
MannKind (MNKD) United States $0.205B 0.00
CorMedix Inc (CRMD) United States $0.204B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
Pfenex (PFNX) United States $0.197B 0.00
Affimed (AFMD) Germany $0.197B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.196B 0.00
POXEL SA FRANCE (PXXLF) $0.194B 0.00
Mersana Therapeutics (MRSN) United States $0.190B 0.00
Spero Therapeutics (SPRO) United States $0.188B 0.00
OSMOTICA PHARM (OSMT) United States $0.187B 0.00
Enzo Biochem (ENZ) United States $0.185B 0.00
Arsanis (XFOR) United States $0.184B 0.00
BioTime (BTX) United States $0.180B 12.00
Compugen (CGEN) Israel $0.177B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.163B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.160B 0.00
XOMA (XOMA) United States $0.159B 0.00
Strongbridge Biopharma (SBBP) United States $0.155B 8.94
Liquidia Technologies (LQDA) United States $0.146B 0.00
Cue Biopharma (CUE) United States $0.144B 0.00
OvaScience (MLND) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.140B 0.00
Adocia (ADOCY) France $0.140B 0.00
TOCAGEN INC (TOCA) United States $0.138B 0.00
Dyadic (DYAI) United States $0.138B 0.00
Northwest Biotherapeutics (NWBO) United States $0.133B 0.00
Arbutus Biopharma (ABUS) Canada $0.133B 0.00
Aptinyx (APTX) United States $0.128B 0.00
Aduro Biotech (ADRO) United States $0.122B 0.00
Menlo Therapeutics (MNLO) United States $0.119B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.119B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.117B 0.00
Alcobra (ARCT) United States $0.117B 0.00
Seres Therapeutics (MCRB) United States $0.115B 0.00
Novavax (NVAX) United States $0.111B 0.00
NantKwest (NK) United States $0.111B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Verastem (VSTM) United States $0.108B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.100B 0.00
Fortress Biotech (FBIO) United States $0.099B 0.00
Trevena (TRVN) United States $0.098B 0.00
Checkpoint Therapeutics (CKPT) United States $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.095B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.086B 0.00
AquaBounty Technologies (AQB) United States $0.085B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.084B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Curis (CRIS) United States $0.082B 0.00
VBI Vaccines (VBIV) United States $0.080B 0.00
Pluristem Therapeutics (PSTI) Israel $0.078B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.078B 0.00
Selecta Biosciences (SELB) United States $0.077B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.075B 0.00
Idera Pharmaceuticals (IDRA) United States $0.070B 0.00
Applied Genetic Technologies (AGTC) United States $0.069B 38.00
VTv Therapeutics (VTVT) United States $0.069B 0.00
Unum Therapeutics (UMRX) United States $0.069B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Signal Genetics (MGEN) United States $0.065B 0.00
Organovo Holdings (ONVO) United States $0.065B 0.00
ARAVIVE, INC (ARAV) United States $0.064B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Protalix BioTherapeutics (PLX) Israel $0.061B 0.00
Invo BioScience (IVOB) United States $0.059B 0.00
Antibe Therapeutics (ATBPF) Canada $0.059B 0.00
Prima BioMed (IMMP) Australia $0.058B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.052B 0.00
DiaMedica Therapeutics (DMAC) United States $0.051B 0.00
Vascular Biogenics (VBLT) Israel $0.051B 0.00
Proteostasis Therapeutics (PTI) United States $0.050B 0.00